Citigroup’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$88.9K Buy
4,943
+1,541
+45% +$30.9K ﹤0.01% 4329
2025
Q4
$79.7K Sell
3,402
-1,291
-28% -$28K ﹤0.01% 4415
2025
Q3
$93.6K Sell
4,693
-380,198
-99% -$6.83M ﹤0.01% 4291
2025
Q2
$5.27M Buy
384,891
+355,614
+1,215% +$3.41M ﹤0.01% 1850
2025
Q1
$324K Sell
29,277
-8,733
-23% -$93.1K ﹤0.01% 3909
2024
Q4
$405K Buy
38,010
+9,882
+35% +$118K ﹤0.01% 3978
2024
Q3
$357K Buy
28,128
+19,796
+238% +$294K ﹤0.01% 3950
2024
Q2
$140K Buy
8,332
+3,494
+72% +$49.7K ﹤0.01% 4059
2024
Q1
$72.6K Sell
4,838
-13,846
-74% -$226K ﹤0.01% 4442
2023
Q4
$280K Buy
18,684
+18,278
+4,502% +$237K ﹤0.01% 3764
2023
Q3
$5.69K Sell
406
-5,818
-93% -$93.4K ﹤0.01% 4685
2023
Q2
$64.4K Sell
6,224
-48,686
-89% -$537K ﹤0.01% 4492
2023
Q1
$507K Buy
54,910
+295
+0.5% +$2.71K ﹤0.01% 3120
2022
Q4
$484K Buy
54,615
+54,284
+16,400% +$514K ﹤0.01% 3198
2022
Q3
$3K Sell
331
-410
-55% -$3.39K ﹤0.01% 5422
2022
Q2
$6K Sell
741
-486
-40% -$3.34K ﹤0.01% 5570
2022
Q1
$11K Sell
1,227
-4,385
-78% -$34.2K ﹤0.01% 5489
2021
Q4
$53K Buy
5,612
+2,169
+63% +$30.6K ﹤0.01% 5037
2021
Q3
$58K Buy
3,443
+1,138
+49% +$18K ﹤0.01% 4662
2021
Q2
$35K Buy
2,305
+574
+33% +$10.4K ﹤0.01% 4991
2021
Q1
$34K Sell
1,731
-2,695
-61% -$57.2K ﹤0.01% 4932
2020
Q4
$80K Buy
4,426
+2,173
+96% +$45.5K ﹤0.01% 5719
2020
Q3
$43K Sell
2,253
-4,751
-68% -$108K ﹤0.01% 5701
2020
Q2
$183K Buy
7,004
+245
+4% +$5.99K ﹤0.01% 5079
2020
Q1
$121K Buy
6,759
+1,376
+26% +$37.2K ﹤0.01% 5192
2019
Q4
$180K Buy
5,383
+3,881
+258% +$106K ﹤0.01% 5272
2019
Q3
$35K Sell
1,502
-4,230
-74% -$138K ﹤0.01% 6366
2019
Q2
$206K Buy
5,732
+5,424
+1,761% +$200K ﹤0.01% 5246
2019
Q1
$11K Buy
+308
New +$12.9K ﹤0.01% 7228

Other funds holding URGN